

# Critical interpretative synthesis of herd immunity for COVID-19 pandemic

Suneela Garg<sup>1,2</sup>, Meghachandra M. Singh<sup>3</sup>, Chetana Prakash Deshmukh<sup>4,5</sup>,  
Nidhi Bhatnagar<sup>6</sup>, Amod L. Borle<sup>6</sup>, Raman Kumar<sup>7</sup>

<sup>1</sup>Professor of Excellence (HAG), National President Elect IAPSM, Country Lead in Addressing Smokeless Tobacco and Building Research Capacity in South Asia (ASTRA), University of York, UK, <sup>2</sup>Department of Community Medicine, Maulana Azad Medical College, <sup>3</sup>Director Professor, Department of Community Medicine, Maulana Azad Medical College, Delhi. <sup>4</sup>Post Doctoral Research Fellow, ASTRA (York), UK, <sup>5</sup>Department of Community Medicine Maulana Azad Medical College, <sup>6</sup>Assistant Professor, Department of Community Medicine, Maulana Azad Medical College, Delhi, <sup>7</sup>Academy of Family Physicians of India, Ghaziabad, Uttar Pradesh, India

## ABSTRACT

**Introduction:** Countries globally are evaluating the concept of herd immunity and its critical role in the control of pandemic. The current paper attempts to conduct a critical interpretative synthesis (CIS) on the role of herd immunity in current COVID-19 pandemic. **Methods:** CIS is tool for developing theoretical framework using interpretation drawn from relevant empirical and non-empirical sources. This review is done by formulating review question for literature search. Purposive sampling of literature was done followed by reciprocal translational analysis of extracted data. **Results:** Herd immunity is indirect protection from a contagious infectious disease when a population is immune either through vaccination or natural immunity developed through previous infection. The reproduction number for COVID-19 in India was found to be 2.56 and herd immunity threshold as 61%. **Discussion:** Exposing 71% young population in India to the SARS-CoV-2 infection can achieve herd immunity but with high morbidity as well as mortality. Vaccine are under process. Feco-oral transmission and reinfection of COVID 19 are major factors to develop or break the circle of herd immunity in community. "Immunity passport" can give false sense of security. Surveillance and seroprevalence studies assess immunity status, gradual exposure of infection to younger population and collaborative partnerships on organizations are few strategies to acquire herd immunity. **Conclusion:** Herd immunity is a measure for prevention and control of COVID-19 pandemic against the backdrop of mortality and morbidity. Vaccine can be boon but if herd immunity is to be acquired by natural infection then preparedness is necessary.

**Keywords:** COVID-19, herd immunity, reproductive number

## Introduction

The pandemic of COVID-19 started as pneumonia of unknown

origin on 19<sup>th</sup> December 2019 in Wuhan, China. On 30<sup>th</sup> January, WHO declared it as a Public Health Emergency of International Concern and within 2 weeks on 12<sup>th</sup> February 2020, WHO renamed the disease as COVID-19. In the course of seven months, COVID-19 infection was transmitted to 215 countries all over the world with more than 32 million confirmed cases (24<sup>th</sup> September 2020) and nearly death count heading towards 1 million.<sup>[1]</sup> India is contributing 17.76% in

**Address for correspondence:** Dr. Meghachandra M. Singh, Director-Professor, Room No 361 Department of Community Medicine, Department of Community Medicine, Maulana Azad Medical College, New Delhi - 110 002, India. E-mail: megharita2@gmail.com

Received: 08-06-2020

Revised: 09-09-2020

Accepted: 13-10-2020

Published: 08-04-2021

### Access this article online

#### Quick Response Code:



Website:  
www.jfmpc.com

DOI:  
10.4103/jfmpc.jfmpc\_1127\_20

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow\_reprints@wolterskluwer.com

**How to cite this article:** Garg S, Singh MM, Deshmukh CP, Bhatnagar N, Borle AL, Kumar R. Critical interpretative synthesis of herd immunity for COVID-19 pandemic. J Family Med Prim Care 2021;10:1117-23.

total cases of COVID 19 and struggling hard to contain the community transmission of the infection with case doubling rate of 46 days.<sup>[2-4]</sup>

India is a country with many challenges in the health care system. With one of the lowest GDP investments for health of 1.28%,<sup>[5]</sup> India's health care system is not capable to address the surge capacity of patients in COVID-19 pandemic. The technical, financial and human resources needed far exceed the current capacity of health care in the country. Hence, initial measures were focused on 'flattening the curve' for COVID-19 cases. As the pandemic evolved there was change in the focus of the pandemic where testing, contact tracing, isolation and treatment were prioritized.

Another major concern is the challenge in implementation of health promotion interventions for the control of COVID-19 along with their sustainability. Practice of frequent handwashing in India as per norms is challenged by the scarcity of water supply and absence of continuous running water in taps. Wearing of masks for prolonged periods is uncomfortable due to extreme weather conditions. Physical distancing is another challenge in Indian scenario due to culture of big families and high population density in urban areas and slums. Lockdown was initiated in India at the earliest with high stringency index from 24<sup>th</sup> March 2020<sup>[3]</sup> in order to prevent transmission of infection by keeping off crowd. But lockdown measures are not sustainable for developing economies like India with poor social support system for the underprivileged.

In this scenario, another available option to combat SARS-CoV-2 virus is herd immunity which can be either artificially acquired through vaccines or naturally acquired by getting exposed to the infection. Vaccines are still under development so countries globally are evaluating the concept of herd immunity and its critical role in the control of pandemic. The current paper attempts to conduct a critical interpretative synthesis (CIS) on the role of herd immunity in current COVID-19 pandemic. CIS is a tool for developing a theoretical framework using insights and interpretation drawn from a wide spectrum of relevant empirical and non-empirical sources.<sup>[4]</sup> Exhaustive review of this is needed with due importance given to media reports, interviews of experts and blogs to bridge the information gap in the limited time frame available.<sup>[6]</sup>

## Methods

The Critical interpretative synthesis (CIS) method was used to review the literature and generate various themes for herd immunity. It was completed in the following steps:

### Formulation of review question

The questions were framed for search of literature. A 360-degree review was done around the following questions

- Can herd immunity be used as one of the strategies to control the COVID-19 pandemic?
- What paradigms and approaches are used to achieve herd immunity?
- What are the challenges in acquiring herd immunity in India?

## Literature search

Search engines like PubMed, EMBASE, Google scholar and Cochrane databases were used for peer-reviewed articles regarding the herd immunity. Blogs and interviews by subject experts were analyzed critically and only relevant matter to the review questions was included. International and National portals of health organizations, Census Commission of India and Ministry of Health and Family Welfare, Government of India were used to extract statistical data. Web search with Google was undertaken to identify the views of epidemiologists on herd immunity. The data regarding herd immunity and technical terms associated with it were retrieved using key words 'herd immunity', 'R0', 'COVID-19' and 'pandemic'.

## Sampling

The number of articles considered for review were based on the inclusion criteria viz. content addressing the review questions along with study design. A purposive sampling technique was used until saturation of the content was observed.

## Quality determination

Priority was given to the relevance of the topic for screening the articles, blogs and interviews rather than methodology or results. This was done purposefully so as to include maximum available content on herd immunity to contribute for the synthesis of theory.

## Data extraction

Repetitive and thorough analysis of the retrieved data was done by highlighting the important concepts, making notes and adding notes and comments as and when required.

## Conducting interpretative synthesis

**Reciprocal translational analysis (RTA)**<sup>[6,7]</sup> was used. The key metaphors, themes, or concepts in each study report were identified. An attempt was then made to understand the concepts. Similar concepts of different studies based on the themes were studied and analyzed and the concept that was 'most adequate' was chosen.<sup>[6]</sup>

## Results

Initial review was done for 186 articles, blogs, newsletters, press notes, interviews of experts in the field of epidemiology and official websites of international and national health organizations, out of which 80 were selected on the basis of concept of CIS, herd immunity and reproduction number. The literature was again screened for the review questions mentioned in the methodology and finally 34 research articles, 5 interviews of subject experts, 9 blogs and data from 5 international and national official websites were used to form the themes. [Figure 1]

## Definition of herd immunity

Herd immunity is indirect protection from a contagious infectious



## Measles

R0 for measles is 12-18, which means that each person with measles on average will infect 12–18 other people in a susceptible population.<sup>[14]</sup> Thus target coverage of measles vaccination is to cover at least 95% population for herd immunity.<sup>[14-16]</sup>

## Mumps

Mumps has R0 of 10-12. Thus, for mumps, the herd immunity threshold of 92% is required for the population to be immune to stop disease transmission.<sup>[17]</sup>

## Swine flu (H1N1)

By the time WHO declared a pandemic of Swine Flu in June 2009, 74 countries had reported laboratory confirmed infections.<sup>[18]</sup> People in Norway successfully developed partial herd immunity to H1N1 virus through vaccinations and natural immunity. Thus H1N1 swine flu has produced antibodies that are protective against variety of flu strains making later outbreaks less severe.<sup>[19-21]</sup>

## COVID-19 on Diamond princess Cruise

Diamond Princess Cruise ship, with 3711 people on board experienced an outbreak of COVID-19. The median R0 of COVID-19 was 2.28 (95% CI of 2.06–2.52) during the early stage.<sup>[22]</sup> In spite of R0 being 2.28 out of total 3711 people on board 712 (19.18%) were symptomatic patients and 331 (8.9%) were asymptomatic but tested positive for COVID 19.<sup>[22]</sup> Rest of the 72% population on the ship remained unaffected even after being exposed to the infection. Diamond princess being a 'natural cohort' can be an example of herd immunity which is to be acquired in case of COVID-19.

## Discussion

### Anticipating herd immunity in India for COVID 19 pandemic

As per the Census data of India 2011, 84.5% population is from the age group of 5 to 65 years. So even if the vulnerable population is left i.e., less than 5 years (10.7%) and more than 65 years (4.8%),<sup>[23]</sup> then as per equation 2, herd immunity threshold of 61% can be easily achieved in India by exposing rest of the population and also excluding people with comorbidities. Currently (as on 23<sup>rd</sup> September 2020) it is seen that 4106 per million population are affected by COVID-19 with 125 deaths per million population.<sup>[24]</sup> A huge chunk of population is yet to be exposed to achieve the target of herd immunity. Probably at this juncture herd immunity needs a careful review on its applicability in controlling the current pandemic.

Primary care physicians play an important role in generation of awareness of herd immunity among population being the first point of contacts for the patients. Early diagnosis by testing asymptomatic patients as well and treatment is integral part of

curbing the pandemic in which primary care physicians are an important link.

### Challenges in achieving herd immunity

Only 2.14% of Americans had been infected even after having highest number of cases globally. Population-weighted seroprevalence after adjusting for test performance was 0.73% in India.<sup>[25]</sup> So, countries are far away from achieving herd immunity threshold of 61% immune population.

However, natural herd immunity, achieved through infection rather than vaccination, can be challenging due to high rate of serious illness and death, with health systems overwhelmed well beyond their surge capacity, even in high-income countries.<sup>[8]</sup> In countries like India with high population density, exposing population to COVID-19 infection in order to acquire herd immunity may prove disastrous and fatal .

Infection fatality rate (IFR) is an important measure to assess the societal cost of achieving global herd immunity. The IFR is defined as the proportion of deaths caused by a certain disease among all infected individuals. Due to asymptomatic cases along with diagnosed cases in infected individuals, the IFR will inherently be lower than the case fatality rate which includes only confirmed cases.<sup>[13]</sup>

Out of all infected patients, 5% are critically ill with severe lung dysfunction, shock or extra-pulmonary organ failure and needs hospitalization and ventilation.<sup>[26, 27]</sup> In the scenario to achieve herd immunity, if 60% of population is exposed to infection then enormous number of people will be very sick, which has huge implications for the country as well as strain for the already overburdened health care settings.

Even when vaccines are available, it is not always possible to achieve herd immunity for very long. In case of SARS-CoV-2 virus, which is seen mutating frequently, will need regular updated vaccines to maintain the immune status which can be expensive in terms of procurement, research and development.

Feco-oral transmission of COVID 19 is another aspect under development. Study of the enteric involvement and viral excretion of SARS-CoV-2 in feces is required to investigate whether fecal concentrations of SARS-CoV-2 RNA correlate with the severity of the disease and presence or absence of gastrointestinal symptoms, and whether fecal SARS-CoV-2 RNA can also be detected in the incubation or convalescence phases of COVID-19.<sup>[28]</sup> This is going to be major factor to develop or break the circle of herd immunity in community.

The World Health Organization and South Korea are investigating about reinfection of SARS-CoV-2 virus. The possible reasons for this were stated as variable immune response of the patient, re-exposure to new strain of virus or false positive test results.<sup>[29]</sup> Thus, reinfection can be major factor to prevent the development of herd immunity.

When a population does not reach the required herd immunity threshold then the overall immunity level is compromised and herd immunity can be lost, putting everyone at risk of the disease.<sup>[8]</sup> In the study done by Wu *et al.* in COVID 19 patients, it was found that formation of neutralizing antibodies against SARS-CoV-2 is very common but longitudinal serological studies will be required to measure the duration of effectiveness of antibodies.<sup>[13]</sup> So far, there is not enough evidence about the effectiveness of antibody-mediated immunity to guarantee the accuracy of an “immunity passport” or “risk-free certificate” for the people to travel or declare as protected against infection and return to their jobs. People once seropositive for COVID-19 may ignore public health advice. The use of such certificates may therefore, increase the risks of continued transmission.<sup>[30]</sup>

Researchers, policymakers and public health advocates can consider herd immunity as an option while planning their post-lockdown strategies to deal with the pandemic but in consideration with that other health promotional measures like handwashing, usage of masks and physical distancing are being followed by the population.

### Strategies to acquire herd immunity

- Fever and Influenza like illness surveillance in the community on a regular basis accompanied with meticulous data monitoring is necessary to evaluate the population exposed to the infection. This will help in estimation of the time required for development of herd immunity.
- Longitudinal serosurveys should be done to assess the immune status of the population for SARS-CoV-2 virus in high and low transmission zones.<sup>[25]</sup>
- Multi-pronged area-specific strategy should be made towards the exit plan from this pandemic moving further to achieve herd immunity.
- Geographically tailored approach should be used in opening of social life with consideration of basic health promotion measures like handwashing and physical distancing.
- In order to achieve the protective level of the immunity, gradual exposure of infection can be strategically planned by exposing young healthy individuals first followed by children and geriatric population. This can be done initially by reopening of schools and colleges followed by restarting industries, agricultural activities, gradually resuming international travel. On the other hand, simultaneously, exposed population will be recovering from the infection.
- The general population should be made aware of the concept of reverse quarantine. Reverse quarantine is isolation of the vulnerable population from the virus. Vulnerable population for COVID-19 infection includes elderly, people with existing co-morbidity, immunocompromised individuals and children less than 10 years.<sup>[31]</sup> All of them should be isolated from those going out in community during the pandemic by decreasing interactions and visits. Preventive measures like physical distancing, hand hygiene and psychological counselling should be followed in order to take care of the

physical and mental health of the vulnerable under reverse quarantine.

- Correct information related to the disease should be circulated among the population including concept of herd immunity. Prevention from infodemics will enable people to fight against the disease in right way.
- Promoting partnership comprising of organizations having common goals and objectives and that combine resources is needed to implement research for vaccine development. Partnerships can reduce duplicity of efforts, ensure synergy of resources, and augment the overall leadership within the country.

### Conclusion

Herd immunity is a measure for prevention and control of COVID-19 pandemic against the backdrop of mortality and morbidity with huge burden on the health care system. If the herd immunity is to be acquired naturally by exposing at least 60% of 5–65 years (84.5%) of population to SARS-CoV-2 infection, then preparedness is necessary in terms of health care facilities with economic implications. Focus is needed on research aiming at appropriate strategies, identification of challenges and approaches to acquire herd immunity along with development of vaccine.<sup>[32-43]</sup> Testing, treatment, tracing, teamwork and tracking with monitoring and surveillance are the tools to measure time required to acquire herd immunity to contain the COVID-19 pandemic and associated multifaceted implications in global and Indian context.

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

### References

1. WHO | World Health Organization [Internet]. [cited 2020 Sep 24]. Available from: <https://www.who.int/>.
2. Press Information Bureau [Internet]. [cited 2020 Sep 24]. Available from: [https://pib.gov.in/PressReleaseDetail.aspx?PRID=1618732.3.BSG-WP-2020-031-v4.0\\_0.pdf](https://pib.gov.in/PressReleaseDetail.aspx?PRID=1618732.3.BSG-WP-2020-031-v4.0_0.pdf) [Internet]. [cited 2020 Sep 20]. Available from: [https://www.bsg.ox.ac.uk/sites/default/files/2020-09/BSG-WP-2020-031-v4.0\\_0.pdf](https://www.bsg.ox.ac.uk/sites/default/files/2020-09/BSG-WP-2020-031-v4.0_0.pdf).
3. Ellen ME, Wilson MG, Vélez M, Shach R, Lavis JN, Grimshaw JM, *et al.* Addressing overuse of health services in health systems: A critical interpretive synthesis. *Health Res Policy Syst* 2018;16:48.
4. CBHI National health portal 2019.pdf [Internet]. [cited 2020 Sep 22]. Available from: <http://www.cbhidghs.nic.in/WriteReadData/1892s/8603321691572511495.pdf>.
5. Dixon-Woods M, Cavers D, Agarwal S, Annandale E, Arthur A, Harvey J, *et al.* Conducting a critical interpretive synthesis of the literature on access to healthcare by vulnerable groups. *BMC Med Res Methodol* 2006;6:35.
6. Noblit GW, Hare RD. Meta-Ethnography: Synthesizing

- Qualitative Studies. SAGE; 1988. 112 p.
7. What is herd immunity? [Internet]. [cited 2020 Sep 21]. Available from: <https://www.gavi.org/vaccineswork/what-herd-immunity>.
  8. Smith DR. Herd Immunity. *Vet Clin North Am Food Anim Pract* 2019;35:593–604.
  9. Anderson RM, May RM. *Infectious Diseases of Humans: Dynamics and Control*. OUP Oxford; 1992. 772 p.
  10. Estimating the serial interval of the novel coronavirus disease (COVID-19): A statistical analysis using the public data in Hong Kong from January 16 to February 15, 2020 | medRxiv [Internet]. [cited 2020 Aug 30]. Available from: <https://www.medrxiv.org/content/10.1101/2020.02.21.20026559v1>.
  11. Rai B, Shukla A, Dwivedi LK. COVID-19 in India: Predictions, reproduction number and public health preparedness [Internet]. *Health Informatics*; 2020 Apr [cited 2020 Sep 24]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.04.09.20059261>.
  12. Herd Immunity: Understanding COVID-19 | Elsevier Enhanced Reader [Internet]. [cited 2020 Sep 24]. Available from: <https://reader.elsevier.com/reader/sd/pii/S1074761320301709?token=AD38E1A628065C77141027D>.
  13. Guerra FM, Bolotin S, Lim G, Heffernan J, Deeks SL, Li Y, *et al.* The basic reproduction number (R0) of measles: A systematic review. *Lancet Infect Dis* 2017;17:e420–8.
  14. Black FL. The role of herd immunity in control of measles. *Yale J Biol Med* 1982;55:351–60.
  15. Krishnamoorthy Y, Sakthivel M, Eliyas S, Surendran G, Sarveswaran G. Worldwide trend in measles incidence from 1980 to 2016: A pooled analysis of evidence from 194 WHO Member States. *J Postgrad Med* 2019;65:160–3.
  16. Abrams S, Beutels P, Hens N. Assessing mumps outbreak risk in highly vaccinated populations using spatial seroprevalence data. *Am J Epidemiol* 2014;179:1006–17.
  17. WHO | What is the pandemic (H1N1) 2009 virus? [Internet]. WHO. World Health Organization; [cited 2020 Sep 22]. Available from: [https://www.who.int/csr/disease/swineflu/frequently\\_asked\\_questions/about\\_disease/en/](https://www.who.int/csr/disease/swineflu/frequently_asked_questions/about_disease/en/).
  18. Coburn BJ, Wagner BG, Blower S. Modeling influenza epidemics and pandemics: Insights into the future of swine flu (H1N1). *BMC Med* 2009;7:30.
  19. Plans-Rubió P. The vaccination coverage required to establish herd immunity against influenza viruses. *Prev Med* 2012;55:72–7.
  20. Immune response to swine flu “extraordinary” [Internet]. nhs.uk. 2018 [cited 2020 Sep 24]. Available from: <https://www.nhs.uk/news/heart-and-lungs/immune-response-to-swine-flu-extraordinary>.
  21. Cruises P. Princess Cruises: Diamond Princess Updates-Notices & Advisories [Internet]. [www.princess.com](http://www.princess.com). 2020 [cited 2020 Sep 22]. Available from: [https://www.princess.com/news/notices\\_and\\_advisories/notices/diamond-princess-update.html](https://www.princess.com/news/notices_and_advisories/notices/diamond-princess-update.html).
  22. Census of India: Age Structure And Marital Status [Internet]. [cited 2020 Sep 23]. Available from: [https://censusindia.gov.in/Census\\_And\\_You/age\\_structure\\_and\\_marital\\_status.aspx](https://censusindia.gov.in/Census_And_You/age_structure_and_marital_status.aspx).
  23. COVID-19 Coronavirus Pandemic, last updated June 08, 2020, 07:20 GMT. Available from: <https://www.worldometer.info/coronavirus/>. [Last accessed on 2020 Sep 08].
  24. Murhekar MV, Bhatnagar T, Selvaraju S, Rade K, Saravanakumar V, Vivian TJW, *et al.* Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey. *Indian J Med Res* 2020;152:48–60. DOI: 10.4103/ijmr.IJMR\_3290\_20.
  25. Thomas-Rüddel D, Winning J, Dickmann P, Quart D, Kortgen A, Janssens U, *et al.* Coronavirus disease 2019 (COVID-19): Update for anesthesiologists and intensivists March 2020. *Anaesthetist* 2020;1–10. doi: 10.1007/s00101-020-00760-3.
  26. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). *Indian J Pediatr* 2020;87:281–6.
  27. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: Is faecal–oral transmission of SARS-CoV-2 possible? *Lancet Gastroenterol Hepatol* 2020;5:335–7.
  28. Mahase E. Covid-19: WHO and South Korea investigate reconfirmed cases. *BMJ* [Internet]. 2020 Apr 15 [cited 2020 Apr 27];369. doi: 10.1136/bmj.m1498.
  29. WHO | “Immunity passports” in the context of COVID-19 [Internet]. [cited 2020 Sep 22]. Available from: <https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19>.
  30. Kerala initiates reverse quarantine, massive isolation facilities to avert further COVID-19 spike [Internet]. *Deccan Herald* 2020 [cited 2020 Sep 13]. Available from: <https://www.deccanherald.com/national/south/kerala-initiates-reverse-quarantine-massive-isolation-facilities-to-avert-further-covid-19-spike-834444.html>.
  31. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. *Immunol Res* 2014;59:118–28.
  32. Covid-19: The Curve Indeed Has Been Flattened, Says Leading Epidemiologist Dr. Muliylil [Internet]. *BloombergQuint*. [cited 2020 Aug 27]. Available from: <https://www.bloombergquint.com/coronavirus-outbreak/covid-19-the-curve-indeed-has-been-flattened-says-leading-epidemiologist-dr-muliylil>.
  33. Delamater PL, Street EJ, Leslie TF, Yang YT, Jacobsen KH. Complexity of the Basic Reproduction Number (R0). *Emerging Infectious Diseases* 2019;25:1–4. doi:10.3201/eid2501.171901.
  34. R0: How Scientists Quantify the Intensity of an Outbreak Like Coronavirus and Its Pandemic Potential | The Pursuit | University of Michigan School of Public Health | Coronavirus | Pandemic [Internet]. [cited 2020 Sep 23]. Available from: <https://sph.umich.edu/pursuit/2020posts/how-scientists-quantify-outbreaks.html>.
  35. Arnesen S, Bærøe K, Cappelen C, Carlsen B. Could information about herd immunity help us achieve herd immunity? Evidence from a population representative survey experiment. *Scand J Public Health* 2018;46:854–8.
  36. Sanche S, Lin Y, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerging Infectious Diseases* 2020;26:1470–7. doi:10.3201/eid2607.200282.
  37. Kaslow RA. *Epidemiology and Control: Principles, Practice and Programs. Viral Infections of Humans* 2014;27:3–38. doi: 10.1007/978-1-4899-7448-8\_1. PMID: PMC7122560.
  38. Kwok KO, Lai F, Wei WI, Wong SYS, Tang JWT. Herd immunity-estimating the level required to halt the COVID-19 epidemics in affected countries. *J Infect* 2020;80:e32–3.
  39. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute

- respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int J Antimicrob Agents* 2020;55:105924.
40. Vincent J-L, Taccone FS. Understanding pathways to death in patients with COVID-19. *Lancet Respir Med* 2020;8:430-2.
  41. Syal K. COVID-19: Herd immunity and convalescent plasma transfer therapy. *J Med Virol* 2020. doi: 10.1002/jmv. 25870.
  42. De Jong MC, Bouma A. Herd immunity after vaccination: How to quantify it and how to use it to halt disease. *Vaccine* 2001;19:2722-8.
  43. Team BSW. DATA STORY: India's doubling time for total corona cases increases to 40.4 days. *Business Standard India* [Internet]. 2020 Sep 15 [cited 2020 Sep 24]. Available from: [https://www.business-standard.com/article/current-affairs/data-story-india-s-doubling-time-for-total-corona-cases-increases-to-40-4-days-120091500541\\_1.html](https://www.business-standard.com/article/current-affairs/data-story-india-s-doubling-time-for-total-corona-cases-increases-to-40-4-days-120091500541_1.html).